Novel Biomarkers of Coronary Artery Disease Risk

Iftikhar J. Kullo

in Mayo Clinic Cardiology

Fourth edition

Published on behalf of © Mayo Foundation for Medical Education and Research

Published in print November 2012 | ISBN: 9780199915712
Published online May 2013 | e-ISBN: 9780199322824 | DOI:

Series: Mayo Clinic Scientific Press

Novel Biomarkers of Coronary Artery Disease Risk

Show Summary Details


Assessment of cardiovascular risk is necessary to inform preventive and therapeutic interventions. Predictive models based on conventional risk factors have less than desired accuracy in predicting CAD risk in an individual, in part because of the widespread prevalence of these risk factors in the general population. Although most patients who suffer a cardiovascular event will have one or more of the conventional risk factors, so do many adults who do not have CAD. Consequently, there is interest in novel biomarkers that might improve cardiovascular risk stratification. Examples include CRP, fibrinogen, NT-proBNP, Lp (a), LDL particle size and number, Lp-PLA2, and genetic susceptibility variants. This chapter provides a brief update on these ‘novel’ risk markers.

Chapter.  1671 words.  Illustrated.

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.